# Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

> **NCT00897312** · — · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** infliximab
- **BIOLOGICAL:** pegylated interferon alfa
- **BIOLOGICAL:** ticilimumab
- **DRUG:** ribavirin
- **OTHER:** high performance liquid chromatography
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00897312
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2016-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00897312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00897312, "Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00897312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*